15th Annual Perspectives in Breast Cancer

21. 8. 2009 - 22. 8. 2009, Westin New York at Times Square, New York, USA

Registrace

Friday, August 21, 2009
Pre-conference: Women’s cancer issues
8:00 am Welcome and introduction
8:05 am Women and lung cancer Antoinette J. Wozniak, MD, FACP
8:30 am Ovarian cancer Deborah K. Armstrong, MD
8:55 am Pregnancy and cancer Mary Cianfrocca, DO
9:20 am Coffee break
9:40 am Cervical cancer Speaker invited
10:05 am Uterine cancer Deborah K. Armstrong, MD
10:30 am Panel discussion
10:45 am CHALLENGING CASES I
This special session will consist of challenging clinical scenarios presented by the audience to a panel of thought leaders (medical oncologists, gynecologic oncologists, surgeons, and radiation oncologists). The interactive nature of this session will enhance the learning process and give attendees a unique opportunity to obtain feedback on difficult patient cases from a panel of experts in the fields of breast cancer and gynecologic oncology.
12:00 pm Lunch break
General Sessions
1:00 pm Welcome and introduction
Session I: Surgery/Radiotherapy
1:10 pm Keynote lecture: Recent advances in the surgical management of breast cancer Speaker invited
1:55 pm Patient selection for breast cancer surgery Stephen F. Sener, MD
2:20 pm Controversies and updates in radiation oncology Krystyna D. Kiel, MD
2:45 pm Panel discussion
3:00 pm Coffee break
Session II: Translational research in advanced/metastatic disease
3:15 pm The role of VEGF inhibitors in breast cancer Maura N. Dickler, MD
3:40 pm HER2-positive metastatic disease and overcoming resistance to anti-HER2 therapy Mohammad Jahanzeb, MD, FACP
4:05 pm Therapeutic options for hormone refractory disease Ruth M. O’Regan, MD
4:30 pm Emerging data on the management of triple-negative breast cancer in the adjuvant and metastatic setting Speaker invited
4:55 pm Treatment of bone metastases in patients with advanced breast cancer Speaker invited
5:20 pm Panel discussion
5:30 pm Adjourn
Saturday, August 22, 2009
8:00 am Welcome to day two
Session III: Prevention, detection, and prognosis
8:10 am BRCA1/BRCA2 in 2009: Clinical updates and ongoing research Speaker invited
8:35 am The genetics and management of patients at high-risk for breast cancer Virginia Kaklamani, MD, DSc
9:00 am Chemoprevention for breast cancer: Where are we headed? Victor G. Vogel, MD, MHS, FACP
9:25 am What is the role of CYP2D6 in pre-menopausal women with ER+ breast cancer? Vered Stearns, MD
9:50 am Panel discussion
10:05 am Coffee break
10:25 am CHALLENGING CASES II
This special session will consist of challenging clinical scenarios presented by the audience to a panel of thought leaders (medical oncologists, gynecologic oncologists, surgeons, and radiation oncologists). The interactive nature of this session will enhance the learning process and give attendees a unique opportunity to obtain feedback on difficult patient cases from a panel of experts in the fields of breast cancer and gynecologic oncology.
12:00 pm Lunch break
Session IV: Molecular profiling
1:00 pm Keynote lecture: Overview of the role of molecular profiling in guiding therapeutic choices for breast cancer treatment Speaker invited
1:45 pm Appropriate management of small cancers Christy A. Russell, MD
2:10 pm Is pCR important in ER+ cancers? Ruth M. O’Regan, MD
2:35 pm Panel discussion
2:50 pm Coffee break
Session V: Adjuvant therapy
3:10 pm Adjuvant therapy: How to make the right choice Speaker invited
3:35 pm What therapy should be given pre-operatively for HER2-positive breast cancers? Mohammad Jahanzeb, MD, FACP
4:00 pm The role of bisphosphonates in the adjuvant setting Speaker invited
4:25 pm Panel discussion
4:40 pm Adjourn

Kontakt: meetings@imedex.com

Web: http://www.imedex....ements/a117-01.asp

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live

Podpora ČOS

Podpora Linkos.cz 

Děkujeme za podporu Linkos.cz! 

I my podporujeme 

Mezi členy ČOS je mnoho DOBRÝCH ANDĚLŮ, kteří přispívají rodinám, jež se vinou nemoci dostali do finanční tísně, ale také těch, kteří zprostředkují pomoc nadace DOBRÝ ANDĚL svým pacientům.